Sandoz Commits to New UN Program to Combat Child Mortality - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sandoz Commits to New UN Program to Combat Child Mortality


Sandoz has made a long-term commitment to supply a key antibiotic formulation as part of the United Nations' new Every Newborn Action Plan, which aims to eliminate preventable deaths of newborn and stillborn babies. The commitment involves providing long-term global supplies of amoxicillin 250 mg dispersible tablets to developing countries via the UN Commission for Lifesaving Commodities.

More than five million children under five are estimated to die worldwide every year, mainly in Africa and Asia, and nearly a quarter of those deaths are due to pneumonia alone, making it the single largest killer in that age range, a press release reported. In 2011, the World Health Organization updated its recommendations for home treatment of pneumonia, establishing dispersible amoxicillin as the newly recommended first-line treatment for pneumonia in children under five.

"Sandoz is proud to be jointly leading the response to the growing global need for this new formulation of a critical anti-infective", said Nick Haggar, head of Western Europe, Middle East, and Africa for Sandoz. "We are committed to working in partnership with all concerned to help prevent the needless deaths of hundreds of thousands of children every year. In our first year of supply, we hope to reach at least 500,000 children worldwide."

Sources: Sandoz

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here